References
- UNODC early warning advisory (EWA) on new psychoactive substances (NPS). United Nations Office on Drugs and Crime; [Cited 2020 Jan 7]. Available from: https://www.unodc.org/LSS/Home/NPS
- UNODC laboratory and scientific section: plant-based substances. United Nations Office on Drugs and Crime; [ Cited 2020 Jan 7]. Available from: https://www.unodc.org/LSS/SubstanceGroup/Details/4b17fe10-91da-477c-bc3d-593136040668
- Anwar M, Law R, Schier J. Kratom (mitragyna speciosa) exposures reported to poison centers – united States, 2010–2015. Mor Mortal Week Rep. 2016;65(29):748–749.
- Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: salvia divinorum and kratom. Clin Toxicol. 2008;46(2):146–152.
- Brandenburg WE, Ward KJ. Mushroom poisoning epidemiology in the United States. Mycologia. 2018;110(4):637–641.
- EMCDDA Drug Profiles. The European monitoring centre for drugs and drug addiction. [cited 2020 Jan 7]. Available from: http://www.emcdda.europa.eu/publications/drug-profiles/salvia
- Reisfield AS. The botany of salvia divinorum (Labiatae). SiDA Contrib Biol. 1993;15:349–366.
- Wasson RG. A new Mexican psychotropic drug from the mint family. Bot Mus Leafl Harv Univ. 1962;20:77–84.
- Cinosi E, Martinotti G, Corazza O. Following the “roots” of kratom (mitragyna speciosa): the evolution of an enhanced from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. Biomed Res Int. 2015;2015:1–44.
- Akers BP, Ruiz JF, Piper A, et al. A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms. Econ Bot. 2011;65(2):121–128.
- Wellbeing courses in South Yorkshire Says, Yorkshire WCIS. Salvia guide - side effects, trip experience, dosage, legality. The Third Wave; [ cited 2019 Oct 25]. Available from: https://thethirdwave.co/psychedelics/salvia/
- National Survey on Drug Use and Health. Key substance use and mental health indicators in the United States: results from the 2015 national survey on drug use and health. 2016 [cited 2019 Dec 3]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2015.pdf
- Keuma C. Facts about Salvia. [Published 2018 Dec 8; cited 2019 Oct 25]. Available from: Recovery.org. https://www.recovery.org/salvia/
- Salvia divinorum drug profile. EMCDDA; [ cited 2019 Oct 25]. Available from: http://www.emcdda.europa.eu/publications/drug-profiles/salvia#prevalence
- Lin P-X, Li J-H, Chen S-H, et al. Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan. J Food Drug Anal. 2014;22(3):370–378.
- El-Khoury J, Sahakian N. The association of salvia divinorum and psychotic disorders: a review of the literature and case series. J Psychoactive Drugs. 2015;47(4):286–292.
- Butelman ER, Kreek MJ. Corrigendum: salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol. 2015;6:190.
- Stiefel KM, Merrifield A, Holcombe AO. The claustrum’s proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Front Integr. 2014;8:1–7.
- Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: A potent naturally occurring nonnitrogenous opioid selective agonist. Proc Natl Acad Sci USA. 2002;99(18):11934–11939.
- Gurlek F, Taaademir E, Teker T. Salvia divinorum: a case report. J Ferment. 2017;7(2). DOI:https://doi.org/10.4172/2167-7972.1000340.
- Mowry M, Mosher M, Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs. 2003;35(3):379–382.
- IBM. Micromedex. Plants-Salvia divinorum.
- González D, Riba J, Bouso JC, et al. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006;85(2):157–162.
- Minns A. Salvia divinorum | California poison control system | UCSF. [ cited 2019 Oct 25]. Available from: https://calpoison.org/news/salvia-divinorum
- Fream K Legal status of Salvia divinorum in US and Europe – theBestSalvia.com – buy Salvia Online. TheBestSalvia.com - Buy Salvia Online; [Published 2017 Apr 13; cited 2019 Oct 25]. Available from: https://thebestsalvia.com/salvia-plant/legal-status-salvia-divinorum-us-europe/
- NIDA. Kratom. National Institute on Drug Abuse website; 2019 Apr 8. Available from: https://www.drugabuse.gov/publications/drugfacts/kratom
- Ahmad K, Aziz Z. Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J Ethnopharmacol. 2012;141(1):446–450.
- Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23–31.
- Suhaimi FW, Yusoff NH, Hassan R, et al., Neurobiology of Kratom and its main alkaloid mitragynine. Brain Res Bull. 126(Pt 1):29–40. 2016.
- Commons K Cracking down on Kratom: FDA investigation, enforcement, seizure, and recall of products reported to contain Kratom. 2018 Nov 30. Available from: https://www.fdli.org/2018/08/update-cracking-down-on-kratom-fda-investigation-enforcement-seizure-and-recall-of-products-reported-to-contain-kratom/
- Reinert J, Leis R, Paplaskas A, et al. Defining the correlation between heroin overdose and length of hospital admissions. J Pharm Tech. 2019;35(6):243–250.
- Trakulsrichai S, Sathirakul K, Auparakkitanon S, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–2429.
- Rech MA, Donahey E, Cappiello Dziedzic JM, et al. New drugs of abuse. Pharmacotherapy. 2015;35(2):189–197.
- Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–6764.
- Olsen EO, O’donnell J, Mattson CL, et al., Notes from the field: unintentional drug overdose deaths with Kratom detected - 27 States, July 2016-December 2017. MMWR Morb Mortal Wkly Rep. 68(14):326–327. 2019.
- Corkery JM, Streete P, Claridge H, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol (Oxford). 2019:269881119862530.
- Overbeek DL, Abraham J, Munzer BW. Kratom (Mitragynine) ingestion requiring naloxone reversal. Clin Pract Cases Emerg Med. 2019;3(1):24–26.
- Diep J, Chin DT, Gupta S, et al. Kratom, an emerging drug of abuse: a case report of overdose and management of withdrawal. A A Pract. 2018;10(8):192–194.
- Aggarwal G, Robertson E, Mckinlay J, et al. Death from Kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19(1):61–63.
- Galbis-reig D. A case report of Kratom addiction and withdrawal. WMJ. 2016;115(1):49–52.
- Buresh M. Treatment of Kratom dependence with buprenorphine-naloxone maintenance. J Addict Med. 2018;12(6):481–483.
- Nelhaus E, Andrews L, Haas J, et al. Neonatal withdrawal following in utero exposure to Kratom. Int J Clin Pediatr. 2018;7(4):55–58.
- Commissioner O. FDA and Kratom. 2019 Sept 11. Available from: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- The Third Wave. The ultimate guide to psilocybin mushrooms. 2019 [cited 2019 Nov 1]. Available from: https://thethirdwave.co/psychedelics/shrooms/
- Roe S, Man L Home office statistical bulletin. Drug Misuse Declared: Findings from the 2005/06 British Crime Survey: England and Wales. 2006 Oct. [cited 2019 Dec 3]. Available from: https://webarchive.nationalarchives.gov.uk/20110220155751/http://rds.homeoffice.gov.uk/rds/pdfs06/hosb1506.pdf
- Reingardiene D, Vilcinskaite J, Lazauskas R. Hallucinogenic mushrooms. Medicina (Kaunas). 2005;41(12):1067–1070.
- Tylš F, Páleníček T, Horáček J. Psilocybin–summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342–356.
- Eivindvik K, Rasmussen KE, Sund RB. Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon. Acta Pharm Nord. 1989;1:295–302.
- Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacol. 2004;172:145–156.
- Tittarelli R, Mannocchi G, Pantano F, et al. Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol. 2015;13(1):26–46.
- Dinis-oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49(1):84–91.
- Beck O, Helander A, Karlson-Stiber C, et al. Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. J Anal Toxicol. 1998;22(1):45–49.
- Chyka PA, Seger D, Krenzelok EP, et al. Position paper: single dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61–87.
- Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65(9):1207–1222.
- Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26–34.
- The Psychedelic Society. Psychedelic mushrooms and cacti. 2019 [cited 2019 Nov 22]. Available from: https://psychedelicsociety.org.uk/mushrooms-cacti
- Leins C States consider decriminalizing magic mushrooms. [ cited 2020 Jan]. Available from: https://www.usnews.com/news/best-states/articles/2019-06-14/states-consider-decriminalizing-magic-mushrooms
- Ingraham C Portugal decriminalised drugs 14 years ago – and now hardly anyone dies from overdosing. [cited 2020 Jan]. Available from: https://www.independent.co.uk/news/world/europe/portugal-decriminalised-drugs-14-years-ago-and-now-hardly-anyone-dies-from-overdosing-10301780.html
- Baer D. 5 countries experimenting with liberal drug laws. [cited 2020 Jan]. Available from: https://www.businessinsider.com/countries-experimenting-with-liberal-drug-laws-2016-3
- WebMD. Kratom. [cited 2020 Jan]. Avaialable from: https://www.webmd.com/vitamins/ai/ingredientmono-1513/kratom
- Whalen A Magic mushrooms guide: where shrooms are legal and how to take psilocybin. [cited 2020 Jan]. Available from: https://www.newsweek.com/magic-mushrooms-psilocybin-shrooms-denver-legal-how-take-1445041
- FDA. FDA statement: statement from FDA Commissioner Scott Gottlieb, M.D., on new warning letters FDA is issuing to companies marketing kratom with unproven medical claims; and the agency’s ongoing concerns about kratom. [cited 2020 Jan]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-warning-letters-fda-issuing-companies-marketing
- Bhalla A. Bedside point of care toxicology screens in the ED: utility and pitfalls. Int J Crit Illn Inj Sci. 2014;4:257–260.